Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP)
ContributorsCiaffi, Laura; Koulla-Shiro, Sinata; Sawadogo, Adrien Bruno; Ndour, Cheik Tidiane; Eymard-Duvernay, Sabrina; Mbouyap, Pretty Rosereine; Ayangma, Liliane; Zoungrana, Jacques; Gueye, Ndeye Fatou Ngom; Diallo, Mohamadou; Izard, Suzanne; Bado, Guillaume; Kane, Coumba Toure; Aghokeng, Avelin Fobang; Peeters, Martine; Girard, Pierre Marie; Le Moing, Vincent; Reynes, Jacques; Delaporte, Eric; Calmy, Alexandra
Published inThe Lancet HIV, vol. 4, no. 9, p. e384-e392
Publication date2017
Abstract
Keywords
- Adult
- Africa South of the Sahara/epidemiology
- Anti-HIV Agents/administration & dosage/economics/therapeutic use
- Antiretroviral Therapy
- Highly Active/methods
- CD4 Lymphocyte Count
- Cameroon/epidemiology
- Drug Therapy
- Combination/methods
- Female
- HIV Infections/drug therapy/epidemiology/virology
- HIV Protease Inhibitors/administration & dosage/therapeutic use
- HIV-1
- Humans
- Lamivudine/administration & dosage/therapeutic use
- Male
- Middle Aged
- Reverse Transcriptase Inhibitors/administration & dosage/therapeutic use
- Senegal/epidemiology
- Viral Load/drug effects
NoteSous-titre : a multicentre, randomised, parallel, open-label, superiority trial.
Affiliation entities
Research groups
Citation (ISO format)
CIAFFI, Laura et al. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP). In: The Lancet HIV, 2017, vol. 4, n° 9, p. e384–e392. doi: 10.1016/S2352-3018(17)30069-3
Main files (1)
Article (Published version)
Identifiers
- PID : unige:112376
- DOI : 10.1016/S2352-3018(17)30069-3
- PMID : 28566227
Journal ISSN2352-3018
